T. Rowe Price Associates
TFFP

T. Rowe Price Associates’s TFF Pharmaceuticals, Inc. Common Stock TFFP Stock Holding History

T. Rowe Price Associates’s Portfolio TFFP Stock Details TFFP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-668
Closed -$18K – 2958
2022
Q4 		$18K Sell
668
-240
-26% -$11.4K ﹤0.01% 2882
2022
Q3 		$93K Hold
908
– – ﹤0.01% 2743
2022
Q2 		$128K Hold
908
– – ﹤0.01% 2711
2022
Q1 		$143K Hold
908
– – ﹤0.01% 2785
2021
Q4 		$201K Buy
908
+248
+38% +$48K ﹤0.01% 2761
2021
Q3 		$127K Hold
660
– – ﹤0.01% 2801
2021
Q2 		$159K Hold
660
– – ﹤0.01% 2771
2021
Q1 		$224K Hold
660
– – ﹤0.01% 2654
2020
Q4 		$236K Hold
660
– – ﹤0.01% 2513
2020
Q3 		$305K Buy
+660
New +$186K ﹤0.01% 2279

Other funds holding TFFP

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

T. Rowe Price Associates's TFFP Position: Q1 2023 in Review

T. Rowe Price Associates sold out of TFF Pharmaceuticals, Inc. Common Stock (TFFP) in Q1 2023, closing a stake of 668 shares — an estimated $18K sold.

T. Rowe Price Associates first reported a position in TFFP in Q3 2020 and held it in 10 quarters. The position peaked at $305K in Q3 2020. 36 funds tracked by Wall St. Rank hold TFFP as of Q1 2023.

  • T. Rowe Price Associates reported no remaining TFF Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • T. Rowe Price Associates sold 668 TFF Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $18K.
  • T. Rowe Price Associates first reported a position in TFF Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 10 quarters.
  • T. Rowe Price Associates's TFF Pharmaceuticals, Inc. Common Stock position peaked at $305K in Q3 2020.
  • 36 funds tracked by Wall St. Rank held TFF Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on T. Rowe Price Associates's 13F filing for Q1 2023, filed 15 May 2023.